Group items tagged

Analytical tools to analyses antibodies and peptides in oncology lead to analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the antibody and peptide cancer drug competitive landscape. A progress analysis on current and emerging drugs for cancer antibodies in oncology lays down a comprehensive framework for further analysis of the field.

A progress analysis on current and emerging drugs on the peptide drug development the reveals promising investment opportunities. Popular products included in the package are Cancer Peptides: From First-in-Class to Best-in-Class; and Peptides in Oncology Drug Pipeline Update 2013.

The tool on apoptosis in oncology also assists in analyzing the vast amount of strategic possibilities that have emerged in apoptotic drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future.

Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012, comprising Aventis Taxotere (docetaxel), Bristol-Myers Squibbs Paraplatin (carboplatin) and Eli Lillys Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau.